[illegible]

溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.
(A joint stock limited liability company incorporated in the People's Republic of China)
Stock code: 2120

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2017

1 INTRODUCTION

1.1 [illegible] (**Board**) [illegible] (**Company**) [illegible] (**Group**, **we** [illegible] **our**) [illegible] 31, 2017 ([illegible] **Reporting Period**) [illegible] 31, 2016.

1.2 [illegible] (**Financial Report**) [illegible] A [illegible] B [illegible] 31, 2016 [illegible] A [illegible] B [illegible]

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the year ended December 31, 2017 *(RMB’000)*	For the year ended December 31, 2016 *(RMB’000)*
[illegible]	**666,436**	415,409
[illegible]	**69,863**	92,139
[illegible]	**(22,027)**	(26,588)
[illegible]	**47,836**	65,551
[illegible]	**49,071**	68,832
[illegible]	**(1,235)**	(3,281)

	As of December 31, 2017 *(RMB’000)*	As of December 31, 2016 *(RMB’000)*
[illegible]	**1,690,401**	1,603,382
[illegible]	**579,904**	562,012
[illegible]	**1,110,497**	1,041,370
[illegible]	**1,051,835**	1,008,383
[illegible]	**58,662**	32,987

3 BUSINESS REVIEW AND OUTLOOK

3.1 Business Review

2017 [illegible]

2017, ... A ... A ...

3.2 Business Highlights

2017, ... 1,400.

3.3 Business Outlook

(.) ... 2015 ... 2017, ... 56.6%, 52.6% ... 53.8% ...

(..) ...

(...)

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review

B666.4 60.4% 2016, B119.9 B546.5 33.2% 2016. 2016, 34.0% (2016: 33.3%). A 35.1% (2016: 34.1%), B191.6 37.1% 2016. B49.1 28.7% 2016, 2016 A- 2017, / A- 28.5% 2016.

4.1.1 Revenue and Cost of Revenue

: ( ) ; ( ) ; ( ) ; ( )

:

	For the year ended December 31,	
	2017	2016
	(RMB'000)	*(B'000)*
	520,175	391,505
	26,386	18,943
	546,561	410,448
	2,318	2,955
	117,557	2,006
Total revenue	**666,436**	415,409

B666.4 , 60.4% 2016, : ( ) 32.9% 39.3%, 33.2% ; ( ) B111.2 B 95.2% (2016: 95.4%) 4.8% (2016: 4.6%).

	For the year ended December 31,	
	2017	2016
	(RMB'000)	*(B'000)*
Treatment and general healthcare services		
[illegible]	**389,494**	285,599
[illegible]	**235,839**	174,139
[illegible]	**153,655**	111,460
Pharmaceutical sales		
[illegible]	**130,681**	105,906
[illegible]	**107,405**	86,970
[illegible]	**23,276**	18,936
Owned hospitals		
[illegible]	**520,175**	391,505
[illegible]	**343,244**	261,109
[illegible]	**176,931**	130,396

[illegible] B520.2 [illegible] B128.7 [illegible] 2016, [illegible] B83.1 [illegible] (2016: B7.3 [illegible]). [illegible] 35.7% [illegible] 2016, [illegible] 34.0% (2016: 33.3%).

[illegible]

	For the year ended December 31,	
	2017	2016
Inpatients		
[illegible]	**3,420**	2,577
[illegible]	**1,248,300**	943,182
[illegible] (%)	**87.8%**	86.5%
[illegible]	**1,095,389**	815,883
[illegible] ([illegible]B'000)	**371,663**	268,555
A[illegible] ([illegible]B)	**339**	329
[illegible] ([illegible]B'000)	**64,896**	48,262
A[illegible] ([illegible]B)	**59**	59
Total inpatient revenue *(RMB'000)*	**436,559**	316,817
Total average inpatient spending per bed-day *(RMB)*	**398**	388
Outpatients		
[illegible]	**160,015**	145,696
[illegible] ([illegible]B'000)	**17,831**	17,044
A[illegible] ([illegible]B)	**111**	117
[illegible] ([illegible]B'000)	**65,785**	57,644
A[illegible] ([illegible]B)	**411**	396
Total outpatient revenue *(RMB'000)*	**83,616**	74,688
Total average outpatient spending per visit *(RMB)*	**522**	513
Total treatment and general healthcare services revenue *(RMB'000)*	**389,494**	285,599
Total pharmaceutical sales revenue *(RMB'000)*	**130,681**	105,906

B436.4 37.8% 2016, ( ) 34.3%; ( ) 2.6% 83.9% (2016: 80.9%).

B83.6 12.0% 2016, ( ) 9.8%; ( ) 1.8%. 16.1% (2016: 19.1%),

36.4% 2016, 74.9% (2016: 72.9%), 23.4% 2016, 25.1% (2016: 27.1%).

	For the year ended December 31,	
	2017	2016
	(RMB'000)	*(B'000)*
[illegible]	**131,949**	103,962
[illegible]	**116,085**	87,060
[illegible]	**20,358**	12,830
[illegible]	**29,331**	17,697
[illegible]	**17,401**	14,018
[illegible]	**9,975**	6,062
[illegible]	**18,145**	19,480
[illegible]	**343,244**	261,109

B343.2 , 31.5% 2016, : ( ) 26.9% ; ( ) 33.3% ; ( ) B19.2 , , A 2016, 62.8%.

38.4% (2016: 39.8%). 33.8% (2016: 33.3%). 14.5% (2016: 11.7%).

B11.7 22.4%

2016,

A 55.7%
(2016: 49.6%).

B117.6 (2016: B2.0),
B111.2 B6.4
A 2016,
B93.1 ,

32.6% (2016: 34.5%), [illegible] 0.518 0 [illegible] ( ) [illegible] 0.518 0 [illegible] ( )

B91.8 31.3 % 2016,
: ( ) 42.7%
; ( ) 42.7%; ( )
B6.4 A-
16.8% (2016: 17.0%),
A-
15.8%, : ( )
;
( ) 2017,

4.1.6 Finance (Expenses)/Income – Net

:

For the year ended

4.1.7 Investment Income/(Loss)

/( ) /( ) /( ) /( ) :

	For the year ended December 31,	
	2017	2016
	(RMB'000)	*(B'000)*
	(6,462)	(6,202)
	350	4,541
	(6,112)	(1,661)

B6.1 (2016: B1.7), A

4.1.8 Assets Impairment Losses

B19.1 (2016: B3.9), 389.7% 2016 3.5% (2016: 1.0%), B7.5 ;

4.1.9 Non-Operating Income (Expenses) and Other Gains

[illegible]

	For the year ended December 31,	
	2017	2016
	(RMB'000)	*(B'000)*
[illegible]	**9,619**	8,019
[illegible]	**196**	549
Non-operating income	**9,815**	8,568
[illegible]	**4,166**	4,478
[illegible]	**7,215**	—
[illegible]	**1,821**	205
Non-operating expenses	**13,202**	4,683
Other gains	**9,417**	—

[illegible] B9.8 [illegible] B9.6 [illegible] B13.2 [illegible] B 6.7 [illegible] A[illegible] B9.4 [illegible]

4.1.10 Income Tax Expense

[illegible] B22.0 [illegible] (2016: B26.6 [illegible]), [illegible] 17.2% [illegible] 2016, [illegible] 24.2% [illegible] 2016. A [illegible] 2017 [illegible] 2016, [illegible] 31.5% [illegible] 28.9%, [illegible]

4.1.11 Total Comprehensive Income

B49.1 28.7% 2016,:

B8.3 ;

B14.9 B ;

B7.5 ;

B6.7 A.

B B18.8 B67.9 35.8% 2016,.

4.2 Financial Position

4.2.1 Inventory

A 31, 2017, B23.5 (31, 2016: B162.8), : () B14.1 (31, 2016: B9.3); () B9.4 (31, 2016: B153.5), B :

B

A

(2012) . . 3-289403

75%

(A . .) (. .) 6,602.26

(A . .) (. .) 30,557.34

30, 2017

4.2.2 Accounts Receivables

A 31, 2017, B232.2 (31, 2016: B142.9), B220.1, 54.0% 31, 2016, 2016.

121 (2016: 117).

4.2.3 Other Receivables and Prepayments

A 31, 2017, B54.6 (31, 2016: B77.0).

4.2.4 Investment Properties

A ... 31, 2017, ... B128.6 ... (... 31, 2016: B72.2 ...), ... B ... (3 & 4) ... II ... B ... (2 ... 11) ... :

...	... B ... (3 & 4)
A ...	...
...	... (2012) ... 3-290617, ... (2012) ... 3-290604, ... (2012) ... 3-290602, ... (2012) ... 3-290616, ... (2017) ... 0136790, ... (2017) ... 0136791, ... (2017) ... 0136792, ... (2017) ... 0136793
...	75%
... (A ...) (...)	3,722.29
... (A ...) (...)	12,854.06
...	...
...	... 29, 2043, ...

II B (2 11)

A

(2012) 3-289403

75%

(A .) (.) 6,602.26

(A .) (.) 11,850.34

29, 2043,

4.2.5 Available-for-Sale Financial Assets

A 31, 2017, B50.0 (31, 2016: B50.0),

4.2.6 Accounts Payable

A 31, 2017, B83.8 (31, 2016: B43.3), B19.8

4.2.7 Advanced from Customers

A 31, 2017, B7.5 (31, 2016: B71.1), B B65.3

4.2.8 Other Payables

A 31, 2017, B99.8 (31, 2016: B38.9),

4.3 Liquidity and Capital Resources

	For the year ended December 31, 2017 (RMB'000)	For the year ended December 31, 2016 (B'000)
[illegible]	**81,499**	49,867
[illegible]	**(223,628)**	(92,788)
[illegible]	**(21,900)**	69,080
[illegible]	**(169,625)**	38,706

4.3.1 Net Cash Generated from Operating Activities

B81.5 B47.8 B18.6 B101.9 B47.6

4.3.2 Net Cash Used in Investing Activities

B223.6 B208.9 B60.5

4.3.3 Net Cash Used in Financing Activities

[illegible] B21.9 [illegible] B90.0 [illegible] B107.7 [illegible].

4.3.4 Significant Investment, Acquisition and Disposal

4.4 Indebtedness

4.4.1 Bank Borrowings

A[illegible] 31, 2017, [illegible] B200.0 [illegible] ([illegible] 31, 2016: B216.7 [illegible]), [illegible] B90.0 [illegible] B106.7 [illegible].

4.4.2 Contingent Liabilities

A[illegible] 31, 2017, [illegible].

4.4.3 Asset Pledge

[illegible] B[illegible] B[illegible] 31, 2017, [illegible] B40.0 [illegible].

4.4.4 Contractual Obligations

[illegible] A[illegible] 31, 2017, [illegible] B334.2 [illegible].

4.4.5 Financial Instruments

4.4.6 Exposure to Fluctuation in Exchange Rates

B.

A 31, 2017,

4.4.7 Gearing Ratio

A 31, 2017, ( ) 34.3% (31, 2016: 35.1%).

4.4.8 Employees and Remuneration Policy

A 31, 2017, 1,860 (31, 2016: 1,348). ( ) B163.7 (2016: B122.9). B101.1 ( ).

5 SIGNIFICANT EVENTS

5.1 CSRC did not approve the Company's application for the initial public offering of A Shares of the Company

A. 23, 2018, A 23, 2018.

5.2 Dividend

B ... A ... 13, 2018, ... 13, 2018 ... 25, 2018 (**Record Date**).

... 14 ... 2018 ... 13 ... 2018 (...). ... A ... 1712 1716, 17 ... , 183 ... 4:30 ... 11 ... 2018.

... 31, 2017 ... B0.15 ... (...). ... 4:30 ... 19, 2018. ... 20, 2018 ... 25, 2018 (...).

... B. ... B ... B ... B. ...

... (中華人民共和國企業所得稅法) ... 1, 2008, ... 10% ... A ...

10%

10%.

10%

10%.

10%

10% 20%

0.0195 ( ) 989 0 (.) 02443 0 (.) 0.0195 ( ) 989 0 (.) 3.923 0

9 COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS

10 IMPORTANT EVENTS AFTER THE REPORTING PERIOD

11 AUDITORS AND ACCOUNTING STANDARDS

31, 2017, A B (PricewaterhouseCoopers), 2017. A A A A

12 FINANCIAL REPORT

12.1 Accounting Policies

A B - B 38 15 2006 (A B A).

2016.

12.2 Change In Accounting Policies

[illegible] 2017, [illegible] A [illegible] B [illegible] 42 [illegible] A [illegible] A [illegible] B [illegible] 16 [illegible] A [illegible] (2017 30). [illegible]:

Content and reason for change in accounting policies	Impacted financial statement item	Amount of impact	
		For the year ended December 31, 2017	For the year ended December 31, 2016
[illegible] 31, 2017 [illegible] 31, 2016 [illegible]	[illegible]	9,417,463	[illegible]
	[illegible]	(9,417,463)	[illegible]
[illegible] 31, 2017 [illegible] 31, 2016 [illegible]	[illegible]	505,331	115,556
	[illegible]	(505,331)	(115,556)

12.2 Consolidated Annual Financial Information

[illegible] A[illegible] [illegible] B[illegible]:

12.2.1 Annual Consolidated Income Statement

		For the year ended December 31, 2017 *RMB*	2016 *B*
1.	**Revenue**	**666,435,528**	415,408,969
	[illegible]: [illegible]	**(449,331,902)**	(272,071,264)
	[illegible]	**(9,780,313)**	(1,169,328)
	[illegible]	**(1,752,173)**	(3,144,314)
	[illegible]	**(91,754,247)**	(69,855,467)
	[illegible] ([illegible])/[illegible]	**(24,262,625)**	24,764,573
	A[illegible]	**(19,104,920)**	(3,902,289)
	A[illegible]	**(6,111,760)**	(1,661,152)
	[illegible]	**(6,461,760)**	(6,201,867)
	[illegible]	**(505,331)**	(115,556)
	[illegible]	**9,417,463**	
2.	**Operating profit**	**73,249,720**	88,254,172
	A[illegible]: [illegible]	**9,814,600**	8,567,750
	[illegible]: [illegible]	**(13,201,645)**	(4,683,423)
3.	**Total profit**	**69,862,675**	92,138,499
	[illegible]: [illegible]	**(22,026,917)**	(26,587,505)
4.	**Net profit**	**47,835,758**	65,550,994

12.2.2 Annual Consolidated Balance Sheets

ASSETS	December 31, 2017 *RMB*	[illegible] 31, 2016 *B*
Current assets		
[illegible]	**279,334,159**	496,614,542
A[illegible]	**232,179,323**	142,938,440
[illegible]	**43,447,939**	54,672,733
A[illegible]	**11,132,676**	22,283,987
[illegible]	**23,532,469**	162,827,694
[illegible]	**12,688,704**	12,688,704
Total current assets	**602,315,270**	892,026,100
Non-current assets		
A[illegible]	**50,000,000**	50,000,000
[illegible]	**89,683,865**	22,429,070
[illegible]	**128,568,963**	72,191,872
[illegible]	**502,649,528**	97,666,540
[illegible]	**22,290,670**	198,066,153
[illegible]	**151,842,863**	125,865,371
[illegible]	**4,823,557**	8,533,389
[illegible]	**96,335,653**	88,855,792
[illegible]	**22,571,944**	20,300,383
[illegible]	**19,318,211**	27,447,253
Total non-current assets	**1,088,085,254**	711,355,823
TOTAL ASSETS	**1,690,400,524**	1,603,381,923

LIABILITIES AND OWNERS' EQUITY	December 31, 2017 *RMB*	[illegible] 31, 2016 *[illegible]B*
Current liabilities		
[illegible]	**90,000,000**	30,000,000
A[illegible]	**83,787,338**	43,271,014
A[illegible]	**7,511,284**	71,147,900
[illegible]	**23,714,318**	19,552,350
[illegible]	**34,912,381**	41,195,655
[illegible]	**99,796,754**	38,922,694
[illegible]	**22,751,104**	54,180,304
Total current liabilities	**362,473,179**	298,269,917
Non-current liabilities		
[illegible]	**110,000,000**	149,950,190
[illegible]	**86,932,300**	86,738,600
[illegible]	**10,556,851**	10,632,800
[illegible]	**9,941,379**	16,420,433
Total non-current liabilities	**217,430,530**	263,742,023
Total liabilities	**579,903,709**	562,011,940
Owners' equity		
[illegible]	**73,040,000**	73,040,000
[illegible]	**808,244,186**	795,604,861
[illegible]	**23,710,012**	18,548,942
[illegible]	**146,840,254**	121,190,550
Total equity attributable to owners of the parent company	**1,051,834,452**	1,008,384,353
[illegible]	**58,662,363**	32,985,630
Total owners' equity	**1,110,496,815**	1,041,369,983
TOTAL LIABILITIES AND OWNERS' EQUITY	**1,690,400,524**	1,603,381,923

12.2.3 Annual Consolidated Statements of Cash Flow

	For the year ended December 31, 2017 *RMB*	2016 *B*
1. Cash flows generated from operating activities		
[illegible]	**502,692,532**	415,653,362
[illegible]	**35,442,492**	28,832,288
Sub-total of cash inflows	**538,135,024**	444,485,650
[illegible]	**(172,416,737)**	(168,939,165)
[illegible]	**(158,956,031)**	(118,573,469)
[illegible]	**(47,590,827)**	(25,779,704)
[illegible]	**(77,672,510)**	(81,326,450)
Sub-total of cash outflows	**(456,636,105)**	(394,618,788)
Net cash flows generated from operating activities	**81,498,919**	49,866,862
2. Cash flows used in investing activities		
[illegible]	**5,675,000**	1,075,000
[illegible]	**—**	2,039,728
[illegible]	**—**	1,500,000
[illegible]	**310,446,972**	256,999,636
Sub-total of cash inflows	**316,121,972**	261,614,364
[illegible]	**(208,923,550)**	(183,852,005)
[illegible]	**(60,498,286)**	(71,708,000)
[illegible]	**—**	(280,995)
[illegible]	**(270,328,000)**	(98,561,000)
Sub-total of cash outflows	**(539,749,836)**	(354,402,000)
Net cash flows used in investing activities	**(223,627,864)**	(92,787,636)

		For the year ended December 31,	
		2017	2016
		RMB	*B*
3.	**Cash flows (used in)/generated from financing activities**		
	[illegible]	**27,020,000**	9,200,000
	[illegible]	**27,020,000**	9,200,000
	[illegible]	**90,000,000**	160,000,000
	[illegible]	**300,000**	[illegible]
	Sub-total of cash inflows	**117,320,000**	169,200,000
	[illegible]	**(107,650,190)**	(67,496,810)
	[illegible]	**(27,084,188)**	(18,260,000)
	[illegible]	**(4,485,351)**	(14,362,579)
	Sub-total of cash outflows	**(139,219,729)**	(100,119,389)
	Net cash flows (used in)/generated from financing activities	**(21,899,729)**	69,080,611
4.	**Effect of changes in foreign exchange rate**	**(5,596,209)**	12,546,534
5.	**Net (decrease)/increase in cash and cash equivalents**	**(169,624,883)**	38,706,371
	A[illegible]	**407,163,542**	368,457,171
6.	**Cash and cash equivalents at end of the year**	**237,538,659**	407,163,542

12.2.4 Annual Consolidated Statement of Changes In Equity

	Equity attributable to owners of the parent company					
	Share capital	Capital surplus	Surplus reserve	Retained earnings	Non-controlling interests	Total owners' equity
Balance at 1 January 2017	**73,040,000**	**795,604,861**	**18,548,942**	**121,190,550**	**32,985,630**	**1,041,369,983**
[illegible]	**—**	**—**	**—**	**49,070,774**	**(1,235,016)**	**47,835,758**
[illegible]	**—**	**—**	**—**	**—**	**27,020,000**	**27,020,000**
[illegible]	**—**	**412,805**	**—**	**—**	**—**	**412,805**
[illegible]	**—**	**12,226,520**	**—**	**—**	**(108,251)**	**12,118,269**
A[illegible]	**—**	**—**	**5,161,070**	**(5,161,070)**	**—**	**—**
[illegible]	**—**	**—**	**—**	**(18,260,000)**	**—**	**(18,260,000)**
Balance at December 31, 2017	**73,040,000**	**808,244,186**	**23,710,012**	**146,840,254**	**58,662,363**	**1,110,496,815**

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Balance at 1 January 2016	73,040,000	797,510,642	11,343,566	77,824,436	2,512,383	962,231,027
[illegible]	—	—	—	68,831,490	(3,280,496)	65,550,994
[illegible]	—	—	—	—	9,200,000	9,200,000
[illegible]	—	2,311,135	—	—	—	2,311,135
[illegible]	—	(4,216,916)	—	—	15,946,066	11,729,150
B[illegible]	—	—	—	—	8,607,677	8,607,677
A[illegible]	—	—	7,205,376	(7,205,376)	—	—
[illegible]	—	—	—	(18,260,000)	—	(18,260,000)
Balance at December 31, 2016	73,040,000	795,604,861	18,548,942	121,190,550	32,985,630	1,041,369,983

12.3 Notes to the Consolidated Annual Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

12.3.1 Accounts receivable

	December 31, 2017 RMB	[illegible] 31, 2016 B
[illegible]	**2,250,000**	[illegible]
[illegible]	**245,277,585**	151,042,945
[illegible]	**247,527,585**	151,042,945
[illegible]	**(15,348,262)**	(8,104,505)
	232,179,323	142,938,440

[illegible] 31, 2017 [illegible] 2016 [illegible]:

	31 December 2017 RMB	31 [illegible] 2016 B
[illegible] 1 [illegible]	**215,379,873**	137,552,824
1 - 2 [illegible]	**29,274,942**	10,835,771
2 - 3 [illegible]	**2,441,995**	2,211,065
[illegible] 3 [illegible]	**430,775**	443,285
	247,527,585	151,042,945

A[illegible]

12.3.2 Accounts payable

A[illegible] 31, 2017 [illegible] 2016,[illegible]:

	December 31, 2017 RMB	December 31, 2016 B
[illegible] 3 [illegible]	**42,078,771**	39,665,783
3- 6 [illegible]	**7,390,442**	2,933,736
6-12 [illegible]	**20,557,648**	223,574
1 - 2 [illegible]	**13,579,346**	103,052
2 - 3 [illegible]	**27,315**	344,869
[illegible] 3 [illegible]	**153,816**	[illegible]
	83,787,338	43,271,014

12.3.3 Revenue and cost of sales

	For the year ended December 31,	
	2017	2016
	RMB	*B*
	546,561,325	410,447,911
	119,874,203	4,961,058
	666,435,528	415,408,969
	354,933,687	270,663,677
	94,398,215	1,407,587
	449,331,902	272,071,264

Revenue and cost of sale from main businesses

	For the year ended December 31,	
	RMB	*B*
	Revenue from main businesses	
	130,681,392	107,405,332
	389,493,815	235,838,816
	26,386,118	11,689,539
	546,561,325	354,933,687

	For the year ended December 31,2016	
	RMB	*B*
	Revenue from main businesses	[illegible]
[illegible]	**105,905,729**	86,970,397
[illegible]	**285,599,012**	174,138,929
[illegible]	**18,943,170**	9,554,351
	410,447,911	270,663,677

12.3.5 Income tax expenses

	For the year ended December 31,	
	2017	2016
	RMB	*B*
[illegible]	**30,123,517**	32,874,281
[illegible]	**(8,096,600)**	(6,286,776)
	22,026,917	26,587,505

[illegible]:

	For the year ended December 31,	
	2017	2016
	RMB	*B*
[illegible]	**69,862,675**	92,138,499
[illegible] 25%	**17,465,669**	23,034,625
[illegible]	**3,741,704**	2,394,514
A[illegible]	**579,395**	(320,322)
[illegible]	**(42,417)**	[illegible]
[illegible]	**415,248**	1,478,688
[illegible]	**207,837**	[illegible]
[illegible]	**(340,519)**	[illegible]
[illegible]	**22,026,917**	26,587,505

12.3.6 Dividends

23, 2018, B B10,956,000 31, 2017, 73,040,000 31, 2017. A .

24, 2017, B B18,260,000 31, 2016. 2016 14, 2017 14, 2017.

13 DEFINITIONS

"A —" 2017 ... 13, 2018

"A... —" ... B...

"B... —" B... (北京怡寧醫院有限公司), ... A... 17, 2015 ... 32.67% ...

"B... —" or "B... —" ...

"... —" ... (蒼南康寧醫院有限公司), ... 15, 2012, ...

"... —" ... (成都怡寧醫院有限公司, ... 成都仁一醫院有限公司), ... 29, 2010 ... 41.67% ...

"... —" ... (成都怡寧醫院有限公司)

"... —" ... (重慶合川康寧醫院有限公司), ... 5, 2015 ... 40% ...

"... —" ... (淳安黃鋒康恩醫院)

"... —" ... B... (...: 2120)

–	A 14
–	
( )–	( )
( )–	( ) B1.00 B
–	A B
–	(溫州怡寧老年醫院有限公司),
– – –	
( )–	( ) B1.00 B
A –	A (杭州安肯醫療科技有限公司 杭州宏瀾信息科技有限公司), 20, 2015 25.94%
–	(杭州慈寧醫院有限公司), 18, 2017,
–	(杭州怡寧醫院有限公司), A 25, 2016,

(廊坊市怡寧醫院管理有限公司), 2, 2015,

(臨海康寧醫院有限公司), 2, 2015,

(台州市路橋怡寧醫院有限公司), 12, 2016,

10

(南昌康寧醫院有限公司), 7, 2016,

(平陽縣長庚醫院有限責任公司精神科)

- ( ) – ( ) ( )

- – (深圳怡寧醫院 深圳市怡寧醫院有限公司), 22, 2014,

- – (四會康寧醫院有限公司), A 19, 2016, .353 0 ( ) 0

(燕郊輔仁中西醫結合醫院)

26, 2015

(樂清康寧醫院有限公司),

3, 2013,

(永嘉康寧醫院有限公司),

12, 2012,

B B

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili

26, 2018